Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

ABSTRACT:

Background

Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear.

Methods

We enrolled two independent cohorts of patients - those with extrapancreatic neuroendocrine tumors and those with pancreatic neuroendocrine tumors - who had received peptide receptor radionuclide therapy or targeted therapy or both. Patients were randomly assigned in a 2:1 ratio to receive cabozantinib at a dose of 60 mg daily or placebo. The primary end point was progression-free survival as assessed by blinded independent central review. Key secondary end points included objective response, overall survival, and safety.

Results

SUBMITTER: Chan JA 

PROVIDER: S-EPMC11821447 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature